<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02938546</url>
  </required_header>
  <id_info>
    <org_study_id>WXIE</org_study_id>
    <nct_id>NCT02938546</nct_id>
  </id_info>
  <brief_title>18F-FDG Metabolism Imaging Monitoring Non-small Cell Lung Cancer Curative Effect of Chemotherapy Multicenter Clinical Study</brief_title>
  <official_title>18F-FDG Metabolism Imaging Monitoring Non-small Cell Lung Cancer Curative Effect of Chemotherapy Multicenter Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Chest Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The subject is going to use 18F-FDG PET/CT to assess different genetic NSCLC metabolism after
      cisplatin chemotherapy and targeted therapy, define the assessment criteria for the role of
      18F-FDG PET/CT in NSCLC treatment respone and at last build multi-centre clinical trial
      platform of molecular classification and molecular imaging for cancer chemotherapy
      assessment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-small-cell lung cancer (NSCLC) is the first leading cause of cancer death in the world.
      Systemic chemotherapy has contributed to the only choice for more than 50% NSCLC patients.
      The genetic abnormalities lead to different therapy response to the same chemotherapy scheme
      in NSCLC patients. At present, early assessment and prediction is the key for optimize NSCLC
      therapy. 18F-FDG PET/CT is a noninvasive cell metabolism reaction molecular imaging
      technology which can assess cancer glucose metabolism sensitively and react cancer
      proliferation to some degree. Hence 18F-FDG PET/CT may be used to assess NSCLC therapy
      response noninvasively. It is a reliable method to individualize NSCLC treatment clinically
      by define the appropriate metabolism response cut-off values and assess time points of
      18F-FDG PET/CT in predicting different genetic NSCLC patients.The subject is going to use
      18F-FDG PET/CT to assess different genetic NSCLC metabolism after cisplatin chemotherapy and
      targeted therapy, define the assessment criteria for the role of 18F-FDG PET/CT in NSCLC
      treatment respone and at last build multi-centre clinical trial platform of molecular
      classification and molecular imaging for cancer chemotherapy assessment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose metabolism discrepancy of different genotype NSCLC as Assessed by EORTC</measure>
    <time_frame>6 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Different genotype NSCLC metabolic response after treatment as Assessed by EORTC</measure>
    <time_frame>6 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Time points of predictive specific genotype NSCLC glucose metabolic response by statistics</measure>
    <time_frame>6 years</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Non-small-cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>before therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>18F-FDG PET/CT performed before therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 days after cisplatin chemotherapy and targeted therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18F-FDG PET/CT performed 3 days after chemotherapy and targeted therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>longer time after cisplatin chemotherapy and targeted therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18F-FDG PET/CT performed before the third cycle chemotherapy and the 7th week targeted therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>18F-FDG</intervention_name>
    <description>18FDG-PET scan was performed 4 weeks before the first administration of therapy or before the third cycle chemotherapy or before the 7th week of targeted therapy and after 3 days chemotherapy and targeted therapy. The lesions were analyzed by nuclear medicine physician and calculate the metabolism response. The size of percent changes was evaluated using the EORTC (European Organization for Research and Treatment of Cancer) PET criteria by oncologist who determine whether the scheme works and the scheme should continue or change. The seleted patients were double blinded to analyse the relationship between metabolism response and chemotherapy response.</description>
    <arm_group_label>before therapy</arm_group_label>
    <arm_group_label>3 days after cisplatin chemotherapy and targeted therapy</arm_group_label>
    <arm_group_label>longer time after cisplatin chemotherapy and targeted therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pathological biopsy for NSCLC; stage III-IV; plan to palliative chemotherapy (such as
             neoadjuvant chemotherapy, convention and targeted therapy) due to unable to surgery;
             not radiation therapy or chemotherapy for 6 months before enrollment; the predictive
             survival time more than half year;

        Exclusion Criteria:

          -  with diabetes and chest radiotherapy chronic disease; brain metastases patients; with
             secondary primary maligmant cancer in 5 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wenhui Xie, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Chest Hospital, Shanghai Jiao Tong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wenhui Xie, PHD</last_name>
    <phone>+8618017321597</phone>
    <email>xknuclear@163.com</email>
  </overall_contact>
  <results_reference>
    <citation>Zhao Y, Wang H, Shi Y, Cai S, Wu T, Yan G, Cheng S, Cui K, Xi Y, Qi X, Zhang J, Ma W. Comparative effectiveness of combined therapy inhibiting EGFR and VEGF pathways in patients with advanced non-small-cell lung cancer: a meta-analysis of 16 phase II/III randomized trials. Oncotarget. 2017 Jan 24;8(4):7014-7024. doi: 10.18632/oncotarget.12294.</citation>
    <PMID>27690345</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang T, Xie J, Arai S, Wang L, Shi X, Shi N, Ma F, Chen S, Huang L, Yang L, Ma W, Zhang B, Han W, Xia J, Chen H, Zhang Y. The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. Oncotarget. 2016 Nov 8;7(45):73068-73079. doi: 10.18632/oncotarget.12230.</citation>
    <PMID>27683031</PMID>
  </results_reference>
  <results_reference>
    <citation>Watanabe K, Shinkai M, Tei Y, Kaneko T. Chemotherapy in Non-Small Cell Lung Cancer Patients Receiving Oxygen Therapy. Oncol Res Treat. 2016;39(10):587-590. Epub 2016 Sep 15.</citation>
    <PMID>27710970</PMID>
  </results_reference>
  <results_reference>
    <citation>Shang J, Ling X, Zhang L, Tang Y, Xiao Z, Cheng Y, Guo B, Gong J, Huang L, Xu H. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1945-53. doi: 10.1007/s00259-016-3420-7. Epub 2016 May 28.</citation>
    <PMID>27236466</PMID>
  </results_reference>
  <results_reference>
    <citation>Ho TY, Chou PC, Yang CT, Tsang NM, Yen TC. Total lesion glycolysis determined per RECIST 1.1 criteria predicts survival in EGFR mutation-negative patients with advanced lung adenocarcinoma. Clin Nucl Med. 2015 Jun;40(6):e295-9. doi: 10.1097/RLU.0000000000000774.</citation>
    <PMID>25783515</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee DH, Kim SK, Lee HY, Lee SY, Park SH, Kim HY, Kang KW, Han JY, Kim HT, Lee JS. Early prediction of response to first-line therapy using integrated 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer. J Thorac Oncol. 2009 Jul;4(7):816-21. doi: 10.1097/JTO.0b013e3181a99fde.</citation>
    <PMID>19487962</PMID>
  </results_reference>
  <results_reference>
    <citation>Huang W, Zhou T, Ma L, Sun H, Gong H, Wang J, Yu J, Li B. Standard uptake value and metabolic tumor volume of ¹⁸F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2011 Sep;38(9):1628-35. doi: 10.1007/s00259-011-1838-5. Epub 2011 May 27.</citation>
    <PMID>21617977</PMID>
  </results_reference>
  <results_reference>
    <citation>Wijesinghe P, Bollig-Fischer A. Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development. Adv Exp Med Biol. 2016;890:1-23. doi: 10.1007/978-3-319-24932-2_1. Review.</citation>
    <PMID>26703796</PMID>
  </results_reference>
  <results_reference>
    <citation>Tafe LJ, Pierce KJ, Peterson JD, de Abreu F, Memoli VA, Black CC, Pettus JR, Marotti JD, Gutmann EJ, Liu X, Shirai K, Dragnev KH, Amos CI, Tsongalis GJ. Clinical Genotyping of Non-Small Cell Lung Cancers Using Targeted Next-Generation Sequencing: Utility of Identifying Rare and Co-mutations in Oncogenic Driver Genes. Neoplasia. 2016 Sep;18(9):577-83. doi: 10.1016/j.neo.2016.07.010.</citation>
    <PMID>27659017</PMID>
  </results_reference>
  <results_reference>
    <citation>Yuneva MO, Fan TW, Allen TD, Higashi RM, Ferraris DV, Tsukamoto T, Matés JM, Alonso FJ, Wang C, Seo Y, Chen X, Bishop JM. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab. 2012 Feb 8;15(2):157-70. doi: 10.1016/j.cmet.2011.12.015.</citation>
    <PMID>22326218</PMID>
  </results_reference>
  <results_reference>
    <citation>Masri S, Papagiannakopoulos T, Kinouchi K, Liu Y, Cervantes M, Baldi P, Jacks T, Sassone-Corsi P. Lung Adenocarcinoma Distally Rewires Hepatic Circadian Homeostasis. Cell. 2016 May 5;165(4):896-909. doi: 10.1016/j.cell.2016.04.039.</citation>
    <PMID>27153497</PMID>
  </results_reference>
  <results_reference>
    <citation>Dejust S, Morland D, Fabre G, Prevost A, Papathanassiou D. 18F-FDG PET/CT Evaluation of Ceritinib Therapy in Metastatic ALK-Positive Non-small Cell Lung Cancer. Clin Nucl Med. 2016 Nov;41(11):879-880.</citation>
    <PMID>27607176</PMID>
  </results_reference>
  <results_reference>
    <citation>Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crinò L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Pérol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Chih-Hsin Yang J, Zhou C, Vokes E. The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. J Thorac Oncol. 2017 Feb;12(2):194-207. doi: 10.1016/j.jtho.2016.10.003. Epub 2016 Oct 8. Review.</citation>
    <PMID>27729297</PMID>
  </results_reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2016</study_first_submitted>
  <study_first_submitted_qc>October 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2016</study_first_posted>
  <last_update_submitted>October 19, 2016</last_update_submitted>
  <last_update_submitted_qc>October 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Chest Hospital</investigator_affiliation>
    <investigator_full_name>Wenhui XIE</investigator_full_name>
    <investigator_title>chief physician</investigator_title>
  </responsible_party>
  <keyword>Non-small-cell lung cancer</keyword>
  <keyword>18F-FDG PET/CT</keyword>
  <keyword>treatment response assessment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

